Chinook Tyee Industry

Asep Medical (formerly Chinook Tyee Industry) is a Canadian biotechnology company dedicated to addressing the global health crises of sepsis and antibiotic resistance. The company was formed through a reverse takeover of Chinook Tyee Industry Ltd. and focuses on commercializing technologies developed at the University of British Columbia. Its primary assets include the SepsetER diagnostic test, which utilizes a gene expression signature to identify sepsis in emergency rooms significantly faster than current methods. Additionally, the company is developing a suite of synthetic antimicrobial peptides designed to treat biofilm-associated infections and suppress harmful inflammation. Asep Medical aims to reduce the high mortality rates associated with sepsis through early detection and innovative therapeutic interventions. The company is publicly traded on the Canadian Securities Exchange under the symbol ASEP.